replication (11), (8;12) and reduced HIV-induced apoptotic cell death in these animals (11;13;14) .
However, HIV-1 viruses highly adapted to replicate in chimpanzee PBMC through multiple in vivo or repetitious in vitro passages could form syncytia, replicated in macrophages and induced apoptosis in CD4+ T cells (12;15-17) . Other proposed mechanisms for long term survival of chimpanzees are the lack of impaired CD4 + T cell renewal (9) , major histocompatibility complex polymorphisms (7), differences in production of CD8+ T-cell Factor (18) , and the role of infiltration of CD8* T cells in lymphoid tissue (19) , which all remain to be clarified (20) .
During HIV-1 infection in humans, increased replicative capacity of the virus is associated with an increase in viral load and subsequent disease progression. In 50% of the cases, a switch from non-syncytium-to syncytium-inducing variants (from CCR5 to CXCR4 usage) (21;22) can be observed, which correlates with an accelerated CD4 T-cell decline and a more rapid disease progression (23) . Although no correlation between disease progression and serumneutralizing antibody responses were found (24;25) , a more broadly effective antibody response was found during the course of chapter|5 infection, which was most pronounced in longterm nonprogressors (26) (27) (28) (29) (30) 
Materials and Methods

Primary cells.
PBMC were isolated from buffy coats obtained from healthy blood donors or from heparinized yena punctures of healthy HIV-1-negaüve chimpanzees by FicollIsopaque density gradient centrifugation. Cells (5 X KK'/ml) were stimulated for 3 days in Iscove's modified Dulbecco medium (IMDM) supplemented with 10% fetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 Ug/ml), and phytohcmatgglutinin (PHA; 5 Hg/ml). Subsequently, cells (lO'/ml) were grown in the absence of PHA, in medium supplemented with recombinant interleukin-2 (10 U/ml, a kind gift of R. Rombouts, Chiron Benelux). Prior to use of chimpanzee PBMC in 50° o tissue culture infective dose (TCID50) or neutralization assays, CD8 + T cells were depleted using anti-CD8-coated magnetic beads (Dynal).
I 1 ruses
Virus isolation and virus stock preparation were performed on PHA-stimulated PBMC according to standard procedures (33) . The IIAN2 isolate was obtained from the European Programme for a Vaccine against AIDS (Programme EVA, Potters Bar, United Kingdom). Isolation and properties of the virus have previously been described (34) . An inoculum of the HIV-LAI strain prepared on the H9 T-cell line was used to experimcntallv infect a chimpanzee. HIVAm S 37 was obtained from an AIDS patient visiting the Academic Medical Center in Amsterdam. The HIV-IIIB stock was also prepared on human PBMC. Each week, vims production in the supernatant was monitored in an in-house p24 antigen capture enzyme-linked immunosorbent assay (ELISA). If sufficient p24 antigen production could be demonstrated, the titer of the virus stock was quantified by determination of the TCID5.1 in PHA-stimulated healthy donor PBMC.
In vivo chimpanzee passage of a T-cell line-adapted (TCLA) and primary HIV-1 isolate All chimpanzees studied were housed in the Biomedical Primate Research Center in Rijswijk, The Netherlands. Ten years after the experimental infection with HIY-LAI (infected in 1984), biological vims clones were reisolated from chimpanzee Maya (ch-Ma). Experimental infection with the primary isolate HAN2 was performed as previously described (6) . A female chimpanzee was inoculated with 100TCID.su (as determined on chimpanzee PBMC) of a virus stock prepared on human PBMC. Blood samples were drawn even' week and revealed a peak in IIIY-1 RNA serum levels at 4.5 weeks post-inoculation, and after 6 weeks antibodies could be detected (6) . From a PBMC sample collected 4.5 weeks after inoculation, biological 1IIV-1 clones (1 IAN2/ch-« vivo) were obtained by cocultivation with human PI IA-stimulatcd PBMC according to standard procedures (33) .
Neutralising agents
Viruses were tested for their relative neutralization sensitivity against increasing concentrations of recombinant sCD4, HIV-1 immunoglobulin (HIVIg), pooled human sera (Ams'f), and the human monoclonal antibodies (MAbs) gpl3, gp68, Ig01bl2, and 1577. HIVIg is a preparation of purified polyclonal immunoglobulin derived from plasma of multiple I IIV-infected donors who had more than 400 CD4+ T cells/ul of blood (35 (36), and IgGlbl2 recognizes the CD4bs of gpl20 (37) . MAb 1577 recognizes a highly conserved epitope of gp41 (residues 735-752) (38) . Autologous serum neutralization of LAI/ch-Ma was studied with three serum samples that were obtained in March 1992, June 1994, and March 1996.
Neutralisation sensitivity of HIV-1 variants Erom each virus isolate, a final inoculum of 10 TCID50 in a volume of 100 ui was incubated for 1 to 2 h at 37°C with increasing concentrations of the neutralizing agents. Subsequently, the mixtures of vims with sCD4, sera, or antibodies were added up to 10' 3-day PHA-stimulated PBMC of either human or chimpanzee origin in 96-well microliter plates. The following day, plates incubated with I riVIg, Ams'T", or chimpanzee serum were washed extensively. On days 7 and 14, vims production in culture supernatants was analyzed by an in-house p24 antigen capture ELISA. Means of quadruplicate experiments of each agent, tested at least twice, were plotted. The percent neutralization was calculated by determining the reduction in p24 production in the presence of the agent compared to the cultures with virus only. When possible 50% (IC50) and 90% (IC90) inhibitory concentrations were determined by linear regression. When sensitivity to neutralization was measured on chimpanzee PBMC, p24 production was monitored until day 10.
In vitro characterisation of virus replication kinetics
Analysis of replication kinetics was performed as described previously (22) . Briefly, PHA-stimulatcd PBMC (5.0 X 10 6 cells/0.5 ml) were incubated with 10 2 TCID50 (1 ml) in a total volume of 1.5 ml for 2 h at 37°C. Virus supernatant was removed, and cells were incubated at a concentration of 1.0 X 10 6 cells /ml. Every day, 50 (il of supernatant was collected to measure p24 production. Fresh PHA-stimulated PBMC were added on days 5, 8 and 11.
I-radiolabeling of V3 peptides and HIV envelope protein
Tn brief, 50-JXl solutions of phosphate-buffered saline (PBS) containing either 20 (ig of peptides or 5 Jig of protein was used for labeling with Na-125 I using chloramine T for 30 s (39). The radiolabeled preparations were purified from free iodine by dialysis and subsequently aliquoted in the presence of protease inhibitor phenylmethyl-sulfonyl fluoride and bovine serum albumin (BSA; fraction V; Sigma) in a final concentration of 0.1% and stored until use at -20°C The peptide V3-IIIB (tip loop, SP104) was prepared as described earlier (40), and the circular V3 peptides were purchased from Zeneca (Cambridge Research Biochemicals) and based on an isolate obtained from patient 168 from the Amsterdam Cohort (ACH.168). The recombinant gpl60 from strain IIIB was expressed via a baculovirus expression system in insect cells and was kindly provided by Phage, La Jolla, California.
Binding of HIV envelope protein and V3 peptides to immobilized antibody (radioimmunoassay format)
The binding studies of antibodies to V3 peptides and gpl6() protein were performed as follows: a serial dilution of serum was mixed with an excess of protein ASepharose beads suspended in PBS containing 0.1% BSA and 0.05% NP-40. After 2 h of incubation head over tail, the beads were washed four times with PBS containing 0.01% Tween 20. Antibodies bound to protein AScpharose beads were incubated head over tail with radiolabeled gpl60 or V3 peptide (ca. 100,000 cpm) in PBS containing 0.1% BSA and 0.05% NP-40 for 16 h at 
Cell surface expression ofCD4, CCBJ, and CXCR4
Flow cytometry was used to analyze the expression of CD4, CCR5 and CXCR4. Human and chimpanzee PBMC (0.5 X 10 6 ) were incubated either with 5 |Ig of anti-CCR5 MAb 2D7 (kindly provided by C. Mackay) or with 5 |lg of IgG2a isotype-matched control MAb (CLB, Amsterdam, the Netherlands) per ml. Cells were then w r ashed and resuspended in 50 U. 1 of fluorescein isothiocyanateconjugated affinity-purified F(ab")2 goat anti-mouse IgG (CLB). Subsequently, cells were incubated first with normal mouse serum (CLB) to diminish background staining, followed by an incubation with PerCP-labeled anti-CD4 MAbs (Becton Dickinson, San Jose, Calif.) and phycoerythrin-labeled anti-CXCR4 MAbs (Pharmingen). Cells were analyzed on the FACScan to determine the levels of cell surface expression. All incubation steps were performed at 4°C for 20 min. Between two incubation steps, two wash steps were performed with PBS supplemented with 0.5° 0 BSA.
Results
Phenotypic changes in HIV-1 variants induced by in vitro passage through chimpanzee cells
We first studied the effect of in vitro passage of Figure|l Neutralization sensitivity as determined on human PHA-stimulated PBMC. (A) One hundred TCID50 of the primary isolate HIVAms37/ml; before and after In vitro passage through chimpanzee PBMC (HIVAms37/ch-/n vitro). Viruses were incubated with increasing concentrations of sCD4, IgGlbl2, gp68, and gpl3 or increasing dilutions of HIVIg and Ams hps as indicated. P24 production was measured, and mean OD values were calculated from quadruplicate cultures from at least duplicate experiments. The percent neutralization was calculated by determining the reduction in supernatant p24 production in the presence of the neutralizing agents relative to control cultures lacking these agents. (B) Neutralization sensitivity of the primary isolates HAN2 and HAN2 after one (HAN2/ch-/n w'iro-pl) or three (HAN2/ch-;n w'tro-p3) In vitro passages through chimpanzee PBMC. Differences in neutralization of HAN2 bv antibody and pooled sera following one passage through chimpanzee PBMC was not observed.
However, the HAN2/clw>7 vitm-p3 isolate had become even more sensitive for sCD4 and also an increased sensitivity for IgGlbl2, Ams h P s ,
HIVIg, and gpl3 MAb could be measured (Table I 
Neutralisation sensitivity of a primary HIV-1 variant after short-term in vivo passage through a chimpanzee
The increased neutralization sensitive phenotype of the primary isolates after in vitro passage through chimpanzee PBMC suggest that adaptation to replicate in these cells selects for a neutralization-sensitive envelope configuration.
We next compared the neutralization sensitivity of the primary neutralization-resistant HAN2
virus and the HIV-1 biological clone reisolated from PBMC from a chimpanzee that had been experimentally infected with this HAN2 virus for (Table | 1 ). There were no differences for gpl3 and gp68 neutralization sensitivity between the primary and in w>o-passaged HAN2 virus.
Neutralisation sensitivity of an HIV-1 variant reisolated 10'years after experimental infection of a chimpanzee
The 
Sensitivity to neutralisation as measured on chimpanzee PBMC
Next, we wanted to exclude that the increased neutralization sensitivity after passage through chimpanzee PBMC in vivo and in vitro is due to the type of target cell used for the neutralization assay. We compared the sensitivities of IIIB, LAI/ch-Ma, HAN2 and HAN2/ch-/« vivo to IgGlbl2 neutralization on chimpanzee PBMC. First, the TCID50 was determined on CD8 Tcell-depleted chimpanzee PHA-stimulated PBMC before IOOTCID50 was used in the neutralization assay. We found the same neutralization sensitivity irrespective of the use of chimpanzee or human PBMC. Both on chimpanzee PBMC and on human PBMC, HIV-IIIB and L\I/ch-Ma were highly sensitive, and the primary HAN2 isolate was resistant, whereas relative to the parental HAN2, the HAN2/ch-z'# vivo exhibited an increased sensitivity for neutralization by IgGlbl2 (Figure | 4) .
Influence of in vivo and in vitro passage of HIV-1 through chimpanzee PBMC on replication kinetics
It has been hypothesized that viral adaptation to a new environment would select for virus variants who most efficiently enter and duplicate in these new target cells (41) (42) (43) . This process 
CCR5 CXCR4
Figure|6 CCR5 and CXCR4 expression on CD4-positive lymphocyte populations of chimpanzee (top panels) or human (bottom panels) PBMC. A threecolor staining protocol was used to assess CCR5 expression (x axis of left panels) and CXCR4 expression (x axis of right panels) on the total number of CD4-positive cells (y axis in all plots).
70 Table 12 Coreceptor usage of primary and chimpanzee- It could be that the affinity of chimpanzee CD4
for HIV-1 gpl20 is different. Although 5-aminoacid differences have been observed between human and chimpanzee CD4, there was no difference in affinity and association rate for TCLA monomeric gpl20 between human or chimpanzee CD4 (10 It cannot be excluded that in chimpanzees, the same evolution of biological properties is ongoing, but with delayed kinetics due to lowlevel replication and consequently slow accumulation of required mutations (64) . In favor of this hypothesis is the observation that serial passage of HIV-1 through chimpanzees, and thus adaptation to this host, indeed seems to result in a virus that is more pathogenic for chimpanzees (15) (16) (17) . In these studies, changes in the neutralization sensitivity of the virus were not 
